Literature DB >> 8603051

The role of the estrogen receptor in tumor progression.

P Lemieux1, S Fuqua.   

Abstract

We will discuss two estrogen receptor (ER) variants that may play a role in breast cancer initiation or progression. One is a truncated receptor, which has been named the exon 5 ER deletion variant, and the other is called a hyper-sensitive variant of the ER that is sensitive to low levels of hormone. Both ER variants differ from the wild-type ER in their hormone binding domains (HBD). The exon 5 ER deletion variant lacks a large portion of the HBD, while the hyper-sensitive ER variant has a point mutation in a conserved region of the HBD. The exon 5 ER deletion variant is transcriptionally active in the absence of hormone, and is thus considered constitutively-active. In contrast, the hyper-sensitive ER variant is functionally active in response to subphysiological concentrations of estrogen. We speculate that both ER variants may form productive heterodimers with wild-type receptor to modify the normal function of ER in the breast.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8603051     DOI: 10.1016/0960-0760(95)00269-3

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  9 in total

1.  ATBF1 inhibits estrogen receptor (ER) function by selectively competing with AIB1 for binding to the ER in ER-positive breast cancer cells.

Authors:  Xue-Yuan Dong; Xiaodong Sun; Peng Guo; Qunna Li; Masakiyo Sasahara; Yoko Ishii; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

2.  Estrogen up-regulates ATBF1 transcription but causes its protein degradation in estrogen receptor-alpha-positive breast cancer cells.

Authors:  Xue-Yuan Dong; Peng Guo; Xiaodong Sun; Qunna Li; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2011-03-02       Impact factor: 5.157

3.  Differential protein expression profiles in estrogen receptor-positive and -negative breast cancer tissues using label-free quantitative proteomics.

Authors:  Karim Rezaul; Jay Kumar Thumar; Deborah H Lundgren; Jimmy K Eng; Kevin P Claffey; Lori Wilson; David K Han
Journal:  Genes Cancer       Date:  2010-03

4.  Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.

Authors:  Yunlong Lu; Lauren M Gutgesell; Rui Xiong; Jiong Zhao; Yangfeng Li; Carlo I Rosales; Michael Hollas; Zhengnan Shen; Jesse Gordon-Blake; Katherine Dye; Yueting Wang; Sue Lee; Hu Chen; Donghong He; Oleksii Dubrovyskyii; Huiping Zhao; Fei Huang; Amy W Lasek; Debra A Tonetti; Gregory R J Thatcher
Journal:  J Med Chem       Date:  2019-12-10       Impact factor: 7.446

5.  Effects of estradiol and tamoxifen on proliferation of human breast cancer cells and human endometrial cells.

Authors:  Bo Zhang; Daoda Chen; Guobin Wang; Yihua Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2003

6.  Activation of the human estrogen receptor by the antiestrogens ICI 182,780 and tamoxifen in yeast genetic systems: implications for their mechanism of action.

Authors:  M W Dudley; C Q Sheeler; H Wang; S Khan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

7.  G-Protein Inwardly Rectifying Potassium Channel 1 (GIRK1) Knockdown Decreases Beta-Adrenergic, MAP Kinase and Akt Signaling in the MDA-MB-453 Breast Cancer Cell Line.

Authors:  Michael W Hance; Madhu S Dhar; Howard K Plummer
Journal:  Breast Cancer (Auckl)       Date:  2008-03-26

8.  Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic regulation of breast cancer cell lines.

Authors:  Howard K Plummer; Qiang Yu; Yavuz Cakir; Hildegard M Schuller
Journal:  BMC Cancer       Date:  2004-12-16       Impact factor: 4.430

9.  Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth.

Authors:  Frederik Holst; Erling A Hoivik; William J Gibson; Amaro Taylor-Weiner; Steven E Schumacher; Yan W Asmann; Patrick Grossmann; Jone Trovik; Brian M Necela; E Aubrey Thompson; Matthew Meyerson; Rameen Beroukhim; Helga B Salvesen; Andrew D Cherniack
Journal:  Sci Rep       Date:  2016-05-10       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.